All In Biotech

NDA 022291 · Novartis

Promacta

Eltrombopag Olamine · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Nov 20, 2008

Approved uses

6

Original approval plus efficacy supplements

Registered trials

22

5 Phase 3, 0 recruiting

FAERS reports

19,469

11,673 serious, 4,302 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions (5.1)] . PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended [see Warnings and Precautions (5.2)] . WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY See full prescribing information for complete boxed warning. In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation. ( 5.1 ) PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic...

What it is approved for

From the label in effect Dec 18, 2025.

PROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. ( 1.3 ) for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: PROMACTA is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) 1.1 Treatment of Thrombocytopenia in Patients With Persistent or Chronic Immune Thrombocytopenia PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients...

Mechanism: Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • PROMACTA · ELTROMBOPAG OLAMINE EQ 100MG ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • PROMACTA · ELTROMBOPAG OLAMINE EQ 75MG ACID · TABLET, ORAL · Prescription · TE AB
  • PROMACTA · ELTROMBOPAG OLAMINE EQ 25MG ACID · TABLET, ORAL · Prescription · TE AB
  • PROMACTA · ELTROMBOPAG OLAMINE EQ 12.5MG ACID · TABLET, ORAL · Prescription · TE AB
  • PROMACTA · ELTROMBOPAG OLAMINE EQ 50MG ACID · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eltrombopag Olamine" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • platelet count decreased3,722
  • death3,223
  • drug ineffective1,482
  • platelet count increased1,069
  • fatigue1,054
  • headache884
  • nausea756
  • diarrhoea738
  • malaise567
  • off label use525
  • product use in unapproved indication513
  • asthenia485

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2009118
2010414
2011674
2012316
2013348
2014513
20151,142
2016707
2017979
20181,126
20191,590
20201,736
20212,198
20222,750
20232,407
20241,235
2025802
2026414

Recalls

1 FDA enforcement reports for this application.

  • May 11, 2019 · Class I · Terminated

    Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Promacta (Eltrombopag Olamine)

2024 spending

$672M

Beneficiaries

6,666

45,852 claims

Per beneficiary

$100,867

$408.06 per unit

View as table
YearSpending
2020$341,789,027
2021$389,486,269
2022$454,825,188
2023$557,676,106
2024$672,379,161

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.